Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

Por Loupakis, Fotios, Cremolini, Chiara, Fontanini, Gabriella, Stasi, Irene, Salvatore, Lisa, Falcone, Alfredo
Publicado em 2009

Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)

Por Salvatore, Lisa, Aprile, Giuseppe, Arnoldi, Ermenegildo, Aschele, Carlo, Carnaghi, Carlo, Cosimelli, Maurizio, Maiello, Evaristo, Normanno, Nicola, Sciallero, Stefania, Valvo, Francesca, Beretta, Giordano D
Publicado no ESMO Open (2017)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

Por Loupakis, Fotios, Bria, Emilio, Vaccaro, Vanja, Cuppone, Federica, Milella, Michele, Carlini, Paolo, Cremolini, Chiara, Salvatore, Lisa, Falcone, Alfredo, Muti, Paola, Sperduti, Isabella, Giannarelli, Diana, Cognetti, Francesco
Publicado em 2010

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management

Por Del Prete, Michela, Giampieri, Riccardo, Loupakis, Fotios, Prochilo, Tiziana, Salvatore, Lisa, Faloppi, Luca, Bianconi, Maristella, Bittoni, Alessandro, Aprile, Giuseppe, Zaniboni, Alberto, Falcone, Alfredo, Scartozzi, Mario, Cascinu, Stefano
Publicado no Oncotarget (2015)

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis

Por Cremolini, Chiara, Antoniotti, Carlotta, Pietrantonio, Filippo, Berenato, Rosa, Tampellini, Marco, Baratelli, Chiara, Salvatore, Lisa, Marmorino, Federica, Borelli, Beatrice, Nichetti, Federico, Bironzo, Paolo, Sonetto, Cristina, Bartolomeo, Maria Di, de Braud, Filippo, Loupakis, Fotios, Falcone, Alfredo, Maio, Massimo Di
Publicado no Cancer Res Treat (2017)

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Por Loupakis, Fotios, Ruzzo, Annamaria, Salvatore, Lisa, Cremolini, Chiara, Masi, Gianluca, Frumento, Paolo, Schirripa, Marta, Catalano, Vincenzo, Galluccio, Nadia, Canestrari, Emanuele, Vincenzi, Bruno, Santini, Daniele, Bencardino, Katia, Ricci, Vincenzo, Manzoni, Mariangela, Danova, Marco, Tonini, Giuseppe, Magnani, Mauro, Falcone, Alfredo, Graziano, Francesco
Publicado em 2011

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

Por Marmorino, Federica, Salvatore, Lisa, Barbara, Cecilia, Allegrini, Giacomo, Antonuzzo, Lorenzo, Masi, Gianluca, Loupakis, Fotios, Borelli, Beatrice, Chiara, Silvana, Banzi, Maria Chiara, Miraglio, Emanuela, Amoroso, Domenico, Dargenio, Francesco, Bonetti, Andrea, Martignetti, Angelo, Paris, Myriam, Tomcikova, Daniela, Boni, Luca, Falcone, Alfredo, Cremolini, Chiara
Publicado no Br J Cancer (2017)

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab

Por Loupakis, Fotios, Cremolini, Chiara, Yang, Dongyun, Salvatore, Lisa, Zhang, Wu, Wakatsuki, Takeru, Bohanes, Pierre, Schirripa, Marta, Benhaim, Leonor, Lonardi, Sara, Antoniotti, Carlotta, Aprile, Giuseppe, Graziano, Francesco, Ruzzo, Annamaria, Lucchesi, Sara, Ronzoni, Monica, De Vita, Ferdinando, Tonini, Giuseppe, Falcone, Alfredo, Lenz, Heinz-Josef
Publicado em 2013

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer

Por Loupakis, Fotios, Moretto, Roberto, Aprile, Giuseppe, Muntoni, Marta, Cremolini, Chiara, Iacono, Donatella, Casagrande, Mariaelena, Ferrari, Laura, Salvatore, Lisa, Schirripa, Marta, Rossini, Daniele, De Maglio, Giovanna, Fasola, Gianpiero, Calvetti, Lorenzo, Pilotto, Sara, Carbognin, Luisa, Fontanini, Gabriella, Tortora, Giampaolo, Falcone, Alfredo, Sperduti, Isabella, Bria, Emilio
Publicado no Br J Cancer (2016)

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients

Por Giampieri, Riccardo, Salvatore, Lisa, Del Prete, Michela, Prochilo, Tiziana, D’Anzeo, Marco, Loretelli, Cristian, Loupakis, Fotios, Aprile, Giuseppe, Maccaroni, Elena, Andrikou, Kalliopi, Bianconi, Maristella, Bittoni, Alessandro, Faloppi, Luca, Demurtas, Laura, Montironi, Rodolfo, Scarpelli, Marina, Falcone, Alfredo, Zaniboni, Alberto, Scartozzi, Mario, Cascinu, Stefano
Publicado no Sci Rep (2016)

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

Por Moretto, Roberto, Cremolini, Chiara, Rossini, Daniele, Pietrantonio, Filippo, Battaglin, Francesca, Mennitto, Alessia, Bergamo, Francesca, Loupakis, Fotios, Marmorino, Federica, Berenato, Rosa, Marsico, Valentina Angela, Caporale, Marta, Antoniotti, Carlotta, Masi, Gianluca, Salvatore, Lisa, Borelli, Beatrice, Fontanini, Gabriella, Lonardi, Sara, De Braud, Filippo, Falcone, Alfredo
Publicado no Oncologist (2016)

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Por Cremolini, Chiara, Marmorino, Federica, Loupakis, Fotios, Masi, Gianluca, Antoniotti, Carlotta, Salvatore, Lisa, Schirripa, Marta, Boni, Luca, Zagonel, Vittorina, Lonardi, Sara, Aprile, Giuseppe, Tamburini, Emiliano, Ricci, Vincenzo, Ronzoni, Monica, Pietrantonio, Filippo, Valsuani, Chiara, Tomasello, Gianluca, Passardi, Alessandro, Allegrini, Giacomo, Di Donato, Samantha, Santini, Daniele, Falcone, Alfredo
Publicado no BMC Cancer (2017)